Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions

Seasonal Influenza Clinical Trial

Official title:

A Phase IV, Multi-Center, Active-Controlled, Observer-Blind Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture (Optaflu®) or in Embryonated Hen Eggs (Agrippal®) in Adults and Elderly With and Without Underlying Medical Conditions, and to Evaluate the Immunogenicity in a Subset of Subjects With Underlying Medical Conditions

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00560066
• Other study ID #: V58P14
• Secondary ID: 2007-002872-32
• Status: Completed
• Phase: Phase 4
• First received: November 16, 2007
• Last updated: January 19, 2016
• Start date: November 2007
• Est. completion date: July 2008

Study information

• Verified date: January 2016
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Paul-Ehrlich-Institute
• Study type: Interventional

Clinical Trial Summary

Evaluation of the safety of Trivalent Subunit Influenza Vaccine Produced either in Mammalian Cell Culture or in embryonated Hen Eggs in subjects 18 years of age and above with and without underlying medical conditions and evaluation of the immunogenicity in a subset of subjects with underlying medical conditions, compared to an egg-based vaccine in a post marketing setting.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1398
• Est. completion date: July 2008
• Est. primary completion date: July 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects 18 years of age and above, mentally competent, willing and able to give informed consent prior to study entry;

2. Able to comply with all study procedures and requirements.

Exclusion Criteria:

1. History of any anaphylaxis, serious vaccine reactions, or hypersensitivity to any vaccine component;

2. Fatal prognosis of an underlying medical condition (<12 months life expectancy);

3. History of Guillain-Barre syndrome;

4. Bleeding diathesis or receiving anticoagulants of the coumarin type;

5. Hospitalization or residence in a nursing care facility;

6. Planned to receive seasonal influenza vaccine outside of this study;

7. Receipt of another vaccine within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrollment in this study;

8. Fever (defined as axillary temperature =38.0°C) or any acute illness within 3 days prior to study vaccination;

9. Receipt of another investigational agent within 30 days prior to enrollment in the study or before completion of the safety follow-up period in another study, whichever is longer, and unwilling to refuse participation in another clinical study through the end safety follow up period of the study;

10. Any condition, which, in the opinion of the investigator, might prevent the subject from participation or interfere with the evaluation of the study objectives;

11. Females who were pregnant or nursing (breastfeeding) mothers, or females of childbearing potential who were sexually active and had not used or did not plan to use acceptable birth control measures during the first 3 weeks after vaccination. Oral, injected or implanted hormonal contraceptive, diaphragm or condom with spermicidal agent or intrauterine device were considered acceptable forms of birth control.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Influenza, Human
• Seasonal Influenza
• Vaccine

Intervention

Biological:
• Cell-derived influenza vaccine
1 dose of 0.5 mL in the deltoid region of the non-dominant arm
• Egg-derived influenza vaccine
1 dose of 0.5 mL in the deltoid region of the non-dominant arm

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Vaccines

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects Who Reported At Least One Reactogenicity Sign After One Vaccination of TIV or cTIV	Safety was assessed as the number of all subjects who reported at least one sign of reactogenicity after one vaccination of egg-derived (TIV) or cell culture-derived (cTIV) influenza virus vaccine from Day 1 through Day 7 post-vaccination.	From Day 1 up to and including Day 7 post-vaccination	Yes
Secondary	Number of Healthy Adults and Elderly Who Reported Solicited Local and Systemic Adverse Events (AEs) After One Vaccination of TIV or cTIV	Analysis was performed on a subset of safety population which included the healthy adults (=18 to =60 years) and elderly (=61 years).	From Day 1 through Day 7 post-vaccination	Yes
Secondary	Number of Adults and Elderly With Underlying Medical Conditions Who Reported Solicited Local and Systemic Adverse Events After One Vaccination of TIV or cTIV	Analysis was performed on a subset of safety population which included the adults (=18 to =60 years) and elderly (=61 years) with underlying medical conditions.	From Day 1 through Day 7 post-vaccination	Yes
Secondary	Percentages Of Subjects With Underlying Medical Conditions Who Achieved Hemagglutination Inhibition (HI) Titer =40 After One Vaccination of TIV or cTIV	Immunogenicity was measured as the percentage of adults (=18 to =60 years) and elderly (=61 years) achieving HI titers =40 at baseline (Day 1) and three weeks (Day 22) after one vaccination of TIV or cTIV for each of three vaccine strains, evaluated using hemagglutination inhibition (HI) egg-derived antigen assay. This criterion is met according to European (CHMP) guideline if the percentage of subjects achieving HI titers =40 is >70% (=18 to =60 years), or >60% (=61 years).	Before vaccination (Day 1) and three weeks after vaccination (Day 22)	No
Secondary	Percentages Of Subjects Who Achieved Seroconversion Or Significant Increase In HI Titers After One Vaccination of TIV or cTIV	Seroconversion or significant increase in HI titer as per CHMP criteria for each of the three strains is defined as the percentage of subjects with a prevaccination HI titer <10 to a postvaccination titer =40; or in subjects with prevaccination HI titer =10, a =4-fold increase in postvaccination HI antibody titer. According to the CHMP criteria, the percentage of subjects achieving seroconversion/significant increase should be >40% (=18 to =60 years) or >30% (=61 years).	Three weeks post-vaccination (Day 22)	No
Secondary	Geometric Mean Titers of Subjects With Underlying Medical Conditions After One Vaccination of TIV or cTIV	Immunogenicity was measured as HI geometric mean titers (GMTs) of subjects with underlying conditions, directed against each of three vaccine strains at baseline (Day 1) and three weeks after vaccination (Day 22) in adults (=18 to =60 years) and elderly (=61 years).	Before vaccination (Day 1) and three weeks after vaccination (Day 22)	No
Secondary	Geometric Mean Ratio of Subjects With Underlying Medical Conditions After One Vaccination of TIV or cTIV	Immunogenicity was measured as the geometric mean ratio (GMR), calculated as the ratio of postvaccination to prevaccination HI GMTs for each of the three strains, three weeks after one vaccination (Day 22) of TIV or cTIV. CHMP criteria is considered fulfilled for each of the three strains if the geometric mean increase GMR (Day 22/Day 1) in HI antibody titer is >2.5 (=18 to =60 years) or >2.0 (=61 Years).	Three weeks post-vaccination (Day 22)	No